403,667 Shares in Codexis, Inc. (NASDAQ:CDXS) Acquired by Tallon Kerry Patrick

Tallon Kerry Patrick purchased a new position in shares of Codexis, Inc. (NASDAQ:CDXS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 403,667 shares of the biotechnology company’s stock, valued at approximately $2,018,000. Codexis makes up approximately 1.9% of Tallon Kerry Patrick’s portfolio, making the stock its 15th largest position. Tallon Kerry Patrick owned approximately 0.50% of Codexis at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CDXS. Intech Investment Management LLC acquired a new position in Codexis during the 3rd quarter worth approximately $66,000. Marshall Wace LLP acquired a new position in shares of Codexis in the 2nd quarter valued at approximately $89,000. Algert Global LLC raised its position in shares of Codexis by 17.1% in the 2nd quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 6,069 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of Codexis by 113.8% in the 2nd quarter. Squarepoint Ops LLC now owns 74,531 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 39,664 shares in the last quarter. Finally, GSA Capital Partners LLP raised its position in shares of Codexis by 83.5% in the 3rd quarter. GSA Capital Partners LLP now owns 99,629 shares of the biotechnology company’s stock valued at $307,000 after purchasing an additional 45,337 shares in the last quarter. 78.54% of the stock is owned by institutional investors and hedge funds.

Codexis Stock Performance

CDXS stock opened at $4.92 on Friday. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. The firm has a market cap of $400.39 million, a P/E ratio of -5.66 and a beta of 2.13. Codexis, Inc. has a 12-month low of $2.53 and a 12-month high of $6.08. The stock’s 50 day simple moving average is $4.77 and its 200 day simple moving average is $3.71.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The firm had revenue of $12.83 million for the quarter, compared to analyst estimates of $11.64 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. During the same period in the prior year, the company posted ($0.26) earnings per share. As a group, equities research analysts predict that Codexis, Inc. will post -0.77 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on CDXS shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 target price on shares of Codexis in a research report on Friday, November 22nd. Benchmark reaffirmed a “hold” rating on shares of Codexis in a research report on Monday, November 4th.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.